lilly verve therapeutics

Order byBest matchMost fresh

Eli Lilly Buys Verve Therapeutics

Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion

Eli Lilly agreed to acquire Verve Therapeutics for about $1 billion upfront, adding a potential treatment for cardiovascular disease to its portfolio.Under the agreement, the pharmaceutical company will buy all of the gene-editing startup’s shares outstanding for $10.

· 1h · on MSN

Eli Lilly Co. to buy gene-editing startup Verve to develop cardiac drugs

· 5h · on MSN

Eli Lilly’s $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring 77%. What to Know.

· 5h

This one-and-done heart-disease treatment just got a $1.3 billion endorsement from Eli Lilly

Verve’s stock VERV soared 76% in premarket trading on Tuesday. If the gains hold through the trading session, they’ll eclipse the previous record one-day gain of 28% for the company’s stock on Oct. 31...

· 7h

Eli Lilly strikes deal to buy Crispr gene-editing biotech Verve

SchaeffersResearch.com · 5h

Biotech Stock Surging on Billion-Dollar Buyout

sharewise1h

Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly

Verve Therapeutics VERV signed a definitive agreement with pharma bigwig Eli Lilly LLY. Per the terms, the pharma giant will acquire all outstanding shares of VERV for $10.50 per share in cash

PharmExec1h

Eli Lilly to Acquire Verve Therapeutics for $1 Billion

With acquisition of Verve Therapeutics, Eli Lilly aims to advance next-generation cardiovascular care through one-time gene editing treatments.